S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:PRTC

PureTech Health (PRTC) Stock Price, News & Analysis

$28.66
-0.74 (-2.52%)
(As of 03/27/2024 ET)
Today's Range
$28.51
$28.71
50-Day Range
$22.05
$30.91
52-Week Range
$17.08
$33.07
Volume
2,527 shs
Average Volume
1,820 shs
Market Capitalization
$773.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

PureTech Health MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.02% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.12mentions of PureTech Health in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.67) to ($3.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.54 out of 5 stars

Medical Sector

881st out of 939 stocks

Pharmaceutical Preparations Industry

393rd out of 422 stocks

PRTC stock logo

About PureTech Health Stock (NASDAQ:PRTC)

PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

PRTC Stock Price History

PRTC Stock News Headlines

PureTech Health (NASDAQ:PRTC) Shares Gap Up to $27.54
PureTech Health (NASDAQ:PRTC) Shares Gap Up to $25.85
Buy Friday, Sell Monday, No Exceptions
Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.
AKLI Mar 2024 3.000 call
PureTech to Present at Two Upcoming Investor Conferences
The Small Biotech with a BIG Cancer Solution
There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.
PureTech to Present at Two Upcoming Investor Conferences
PureTech Health plc (PRTC)
LSE:PRTC (PureTech Health plc)
PRTC PureTech Health plc
PureTech outlook for 2024
See More Headlines
Receive PRTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PureTech Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
4/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRTC
Employees
111
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$15.62 million
Book Value
$19.64 per share

Miscellaneous

Free Float
25,564,000
Market Cap
$773.82 million
Optionable
Not Optionable
Beta
1.20
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Ms. Daphne Zohar (Age 53)
    Founder, CEO & Executive Director
    Comp: $1.01M
  • Dr. Bharatt M. Chowrira J.D. (Age 59)
    Ph.D., President & Executive Director
    Comp: $800.55k
  • Dr. Robert S. Langer Jr. (Age 75)
    Ph.D., Co-Founder & Non-Executive Director
    Comp: $145k
  • Dr. David R. Elmaleh Ph.D. (Age 76)
    Co-Founder & Senior Advisor
  • Ms. Allison Mead Talbot
    Head of Communications & Investor Relations
  • Mr. Spencer Ball
    Senior Vice President of Human Resources
  • Dr. Eric Elenko Ph.D. (Age 51)
    Chief Innovation & Strategy Officer
  • Ms. Aleksandra Filipovic M.D.
    Ph.D., Head of Oncology
  • Ms. Cheryl Murphy Ph.D.
    Head of Grants Management & Strategy
  • Ms. Anita Terpstra J.D.
    Ph.D., Senior VP & Head of Intellectual Property

PRTC Stock Analysis - Frequently Asked Questions

How have PRTC shares performed in 2024?

PureTech Health's stock was trading at $28.18 at the beginning of 2024. Since then, PRTC shares have increased by 1.7% and is now trading at $28.66.
View the best growth stocks for 2024 here
.

When is PureTech Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024.
View our PRTC earnings forecast
.

How do I buy shares of PureTech Health?

Shares of PRTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRTC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners